| Name | 740 Y-P |
| Description | 740 Y-P (740YPDGFR) is a PI3K activator with cell permeability. 740 Y-P binds GST fusion proteins containing the N-and C-terminal SH2 domains of p85. |
| In vitro | METHODS: C2 muscle cells were treated with 740 Y-P (50 μg/mL) for 48 hours, and the cell cycle was observed and analyzed using an ultraviolet fluorescence microscope.
RESULTS: Mitosis in the 740 Y-P-specific stimulation medium was superior to EGF or FGF in stimulating the entry into the S phase. It showed that the percentage of S phase cells in C2 cells was 48.3%. [1]
METHODS: PC12 cells were treated with 740 YP (30 μM) for 24 hours, and the LC3-II/LC3-I levels were detected by western blot.
RESULTS: 740 YP significantly inhibited the LC3-II/LC3-I levels in PC12 cells induced by GO. [2] |
| In vivo | METHODS: To study the neuroprotective effect of 740 Y-P, 740 Y-P (10 mg/kg) was intraperitoneally injected into the rat model of Alzheimer's disease (AD) for 6 weeks.
RESULTS: 740 Y-P can reduce the ROS (reactive oxygen species) level in hippocampal tissue after treatment with Aβ(25-32), and increase the phosphorylation degree of AKT and PI3K. This indicates that 740 Y-P has a certain neuroprotective effect in vivo, which may be achieved by activating the PI3K/Akt signaling pathway. [3]
METHODS: To study the role of 740 Y-P in cardiac hypertrophy, 740 Y-P (10 mg/kg) was intraperitoneally injected into mice for 6 weeks.
RESULTS: 740 Y-P can significantly increase the ratio of heart weight to body weight (HW/BW) and the ratio of heart weight to tibial length (HW/TL), and increase the cross-sectional area of cardiomyocytes. Furthermore, 740 Y-P can also increase the expression of hypertrophy related genes such as ANP, BNP and β-MHC in cardiomyocytes, indicating that it can promote cardiac hypertrophy in vivo. [4]
METHODS: To study the analgesic effect of 740 Y-P, 740 Y-P (1, 5, 10, 20 µg/5 µL) was intrathecally injected into a mouse model of chronic constriction injury of the sciatic nerve (CCI).
RESULTS: At doses of 10 and 20 µg/5 µL, 740 Y-P can significantly alleviate tactile and thermal hypersensitivity caused by CCI. 740 Y-P showed significant analgesic effects within 1.5, 3 and 5 hours after injection, but the effect was no longer significant after 24 hours. [5] |
| Storage | store at low temperature,store under nitrogen,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (15.29 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (0.61 mM), Sonication is recommended.
H2O : 5.5 mg/mL (1.68 mM), when pH is adjusted with HCl. Sonication is recommmended.
|
| Keywords | VSMC | thoracic | SH2 | PI3K | p85 binding | Autophagy | aortic | alzheimer's disease | 740 Y-P | 740 YP | 740 Y P |
| Inhibitors Related | Stavudine | Aceglutamide | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Hyaluronic acid | Hydroxychloroquine | Guanidine hydrochloride | Paeonol | Sodium butanoate | Naringin | Alginic acid | Gefitinib |
United States
